NEW YORK, Nov. 24 /PRNewswire/ -- Xenazine(R) (tetrabenazine) Tablets, the first and only U.S. Food and Drug Administration (FDA) approved drug for the treatment of chorea associated with Huntington's Disease (HD), is now available in the United States. Patients, caregivers, physicians and family members have been waiting for decades for a single treatment option. The Huntington's Disease Society of America is pleased that for the first time ever people with HD will have an approved option to consider to treat their chorea. Xenazine, which lessons the effects of chorea, will be distributed by Ovation Pharmaceuticals through a network of specialty pharmacies.
"The launch of Xenazine represents a significant milestone for the patients, families and caregivers affected by HD. After years of advocating for the approval of Xenazine, we are so pleased that it is now available here in the U.S. and that Ovation is committed to making this product accessible to as many individuals as possible who are living with this rare and devastating condition," said Barbara Boyle, National Executive Director/CEO, Huntington's Disease Society of America. Ovation has developed comprehensive patient support programs to ensure that as many qualified individuals as possible can receive Xenazine and to mitigate patients having problems accessing the drug due to financial constraints.
To find out more about Xenazine and if it is the right treatment for you: -- Go see your physician -- Call 1-888-882-6013 -- Visit Xenazineusa.com
Huntington's Disease is a devastating hereditary brain disorder with limited effective treatment options. HD slowly diminishes the affected individual's ability to walk, talk and reason. Eventually, the person with HD becomes totally dependent upon others for his or her care. Huntington's Disease profoundly affects the lives of entire families -- emotionally, socially and economically More than a quarter of a million Americans have HD or are "at risk" of inheriting the disease from an affected parent. HD affects as many people as Hemophilia, Cystic Fibrosis or ALS. HD affects males and females equally in all ethnicities. Each child of a person with HD has a 50 percent chance of inheriting the fatal gene. Everyone who carries the defective gene will develop the disease.
For some individuals, HD begins with chorea, a symptom present in an estimated 90 percent of people with HD. Chorea is a debilitating movement disorder characterized by excessive, involuntary and repetitive movements that are one of the most visible manifestations of Huntington Disease. Chorea interferes with individuals' ability to perform activities of daily living, including dressing, bathing and caring for themselves.
About Huntington's Disease Society of America
Huntington's Disease Society of America (HDSA) is a national non-profit organization dedicated to finding a cure for Huntington's Disease (HD) while providing support and services for those living with HD and their families. HDSA promotes and supports both clinical and basic HD research, aids families in coping with the multi-faceted problems presented by HD and educates the families, the public and health care professionals about Huntington's Disease. For more information call (800)-345-HDSA, visit http://www.hdsa.org or e-mail firstname.lastname@example.org.
Copyright©2008 PR Newswire.
All rights reserved